
 
                                                 
                                                 
                                                 
                                                 
                                                 
                                                 
                                         
                                         
                                         
                                     
                                    
 
                                                                 
                                                                 
                                                                 
                                                                 
                                                                 
                                                                 
                                                                 
                                             
                                             
                                             
                                                 
                                            The FDA approved 50 novel drugs in 2021, maintaining the five-year average, and 2022 looks set to follow with not only novel COVID-19 treatments and vaccines expected to launch. Trends across the pharmaceutical industry have returned to a steadier state after the initial supply and demand issues of the pandemic, although regional and therapy area pockets of uncertainty remain. Loss of patent protection (LoP), and generic and biosimilar launches also crowd the calendar, with some therapy areas more strongly affected, but impacts do not outweigh expected pipeline launch growth, indicating growth for the sector in 2022.